|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Heterozygous and homozygous factor V G1691A, factor II G20210A, and homozygous MTHFR C677T were found to be independent risk factors for VTE, with odds ratios of 16.3, 3.6, and 2.1, respectively.
|
10073951 |
1999 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genotyping for mutations that are possible causes of moderate hyperhomocysteinemia, such as the thermolabile variant (C677T) of methylenetetrahydrofolate reductase (MTHFR), does not seem useful to identify individuals at higher risk for venous thromboembolism.
|
11011848 |
2000 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
The C677T polymorphism of the 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene has been postulated to be a genetic risk factor for venous thromboembolism and osteonecrosis in Caucasians, but this relationship has not been established in other populations.
|
20229089 |
2010 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prothrombin 20210 G-->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy.
|
10759281 |
2000 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Factor V leiden G1691A/R506Q (FVL), prothrombin G20210A (FII) and methylenetetrahydrofolate reductase (MTHFR) C677T are related genetic risk factors for venous thromboembolism.
|
22528331 |
2012 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Fasting total homocysteine (tHcy) and the methylenetetrahydrofolate reductase (MTHFR) C677T mutation were evaluated in 91 patients with venous thromboembolism and without acquired thrombophilia, and in 91 age-matched and sex-matched controls.
|
11943942 |
2002 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Factor V Leiden (Factor V G1691A), prothrombin gene mutation G20210A, and homozygous C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene are known to predispose venous thromboembolism (VTE).
|
19520679 |
2010 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Elevated plasma homocysteine (tHcy) and the MTHFR c.677C>T variant have been postulated to increase the risk of venous thromboembolism (VTE), although mechanisms and implications to pediatrics remain incompletely understood.
|
23866722 |
2013 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Role of soluble P-selectin and methylenetetrahydrofolate reductase gene polymorphisms (677C>T) in Egyptian patients with venous thromboembolism.
|
22688557 |
2012 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
We performed a prospective study to evaluate the prevalence and clinical significance of four gene variations (factor V Leiden [FVL], factor II G20210A, factor XIII Val34Leu and MTHFR C677T) in cancer patients, with and without VTE.
|
12757770 |
2003 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Insofar as the inherited prothrombotic single nucleotide polymorphisms (SNPs) factor V G1691A (FV-Leiden), prothrombin (PRT) G20210A, and methylenetetrahydrofolate reductase (MTHFR), C677T are inherited risk factors of venous thromboembolism (VTE), the aim of this study was to determine the prevalence of single and combined SNPs in 198 patients with documented deep venous thrombosis (DVT), and 697 control subjects, and to estimate the associated risks.
|
16082606 |
2005 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are considered risk factors for venous thromboembolism.
|
15886665 |
2005 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
No significant association with VTE was found for homozygous C677T MTHFR (OR: 1.38; 95 % confidence intervals [CI]: 0.98-1.93), whereas the risk was increased in carriers of either heterozygous FVL or PT20210 (OR = 4.22; 95 % CI: 3.35-5.32; and OR = 2.79;95 % CI: 2.25-3.46, respectively), in double heterozygotes (OR = 3.42; 95 %CI 1.64-7.13), and in homozygous FVL or PT20210A (OR = 11.45; 95 %CI: 6.79-19.29; and OR: 6.74 (CI 95 % 2.19-20.72), respectively).
|
23900608 |
2013 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
To clarify the contribution of C677T MTHFR mutation in arterial occlusive disease (AOD) or venous thromboembolism (VTE), we performed a case-controlled study including 160 cases with AOD and 180 cases with VTE attending our referral center and compared them with 200 matched healthy controls.
|
10477457 |
1999 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single point mutations in the genes coding for factor V [G1691A; Leiden], prothrombin [PRT; G20210A], and methylenetetrahydrofolate reductase [MTHFR, C677T] were shown to be major inherited predisposing factors for venous thromboembolism.
|
15353918 |
2004 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, frequencies of FV G1691A, PT G20210A, and MTHFR C677T mutations are higher in patients with VTE.
|
21078611 |
2012 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Methylenetetrahydrofolate reductase (MTHFR) C677T single nucleotide polymorphism is a major inherited risk factor of venous thromboembolism.
|
23749065 |
2013 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conclude that screening for the C677T mutation of the methylenetetrahydrofolate reductase gene should not be recommended in unselected patients with VT.
|
9217179 |
1997 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study suggests that the homozygous C677T mutation in the MTHFR gene might be a risk factor of VTE in patients with spontaneous events and without other common genetic risk factors.
|
11124649 |
2000 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
The findings from our meta-analysis support the associations of MTHFR C677T polymorphism with VTE risk in the Chinese population.
|
25149317 |
2015 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
In contrast, factor V Leiden, the G20210A prothrombin gene mutation, and the C677T MTHFR gene mutation are not genetic risk factors among Thai patients with VTE.
|
18192106 |
2007 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the present study, we have focused on the prevalence of methylenetetrahydrofolate reductase (MTHFR) C677T, dihydrofolate reductase (DHFR) 19-bp deletion within intron 1, factor V Leiden (FVL), and prothrombin (PT) G20210A polymorphisms in cancer patients with and without VTE.
|
18682947 |
2009 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
The C677T MTHFR polymorphism is suggested to be associated with the risk for VTE.
|
22992862 |
2012 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
The C677T mutation of the methylenetetrahydrofolate reductase gene, which may lead to hyperhomocysteinemia, is also considered a risk factor for VTE in some studies.
|
17401546 |
2007 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
MTHFR C677T had no association with VTE risk in pregnancy (ORG 1.24; 95% CI 0.88-1.73).
|
26115054 |
2015 |